Comparative Pharmacology
Head-to-head clinical analysis: APRESAZIDE versus HARMONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESAZIDE versus HARMONYL.
APRESAZIDE vs HARMONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresazide is a combination of hydralazine, a direct-acting vasodilator that relaxes arteriolar smooth muscle, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
1 capsule (hydralazine 25 mg / hydrochlorothiazide 25 mg) orally twice daily; may increase to 2 capsules twice daily if needed. Maximum: 4 capsules daily.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); Hydrochlorothiazide: 6-15 hours. Clinical context: Dosing interval typically 12 hours for hydralazine component.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Hydralazine: ~75% renal (metabolites), <10% unchanged; Hydrochlorothiazide: >95% renal (unchanged).
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihypertensive
Antihypertensive